eBOOKS BY CATEGORY
Your Account
Myeloproliferative Neoplasms
Critical Concepts and Management
Price
Quantity
£124.17
(To see other currencies, click on price)
PDF
Add to basket  

MORE ABOUT THIS BOOK

Main description:

This book focuses on three of the main categories of myeloproliferative neoplasm: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Relevant laboratory and clinical advances are comprehensively covered, and great emphasis is placed on the practical issues that challenge physicians in their daily practice. The main topics considered thus include contemporary diagnostic  approaches, the value and limitations of mutation screening for diagnostic and  prognostic purposes, risk stratification in terms of both survival and other  disease complications such as leukemic transformation and thrombosis, and  modern therapeutic strategies, including conventional drugs, allogeneic stem cell  transplantation, and experimental drugs still under study. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.


Feature:

Comprehensively covers laboratory and clinical advances in polycythemia vera, essential thrombocythemia, and primary myelofibrosis

 

Places special emphasis on the practical issues that challenge physicians in their daily practice

 

Includes recommendations for the optimization and standardization of treatment

 

Written by leading experts in the field


Back cover:

Myeloproliferative neoplasms (MPNs) are clonal stem cell diseases that, under the World Health Organization classification, are subcategorized into eight clinicopathologic entities. The current book focuses on three of these categories: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. A number of important questions regarding the diagnosis, prognosis, and treatment of these diseases have arisen following the discovery of the JAK2 V617F mutation in the majority of patients with bcr/abl-negative MPNs.

 

This book comprises evidence-based reviews and expert consensus results. It offers comprehensive coverage of relevant laboratory and clinical advances and places great emphasis on the practical issues that challenge physicians in their daily practice. The main topics considered thus include contemporary diagnostic  approaches, the value and limitations of mutation screening for diagnostic and  prognostic purposes, risk stratification in terms of both survival and other  disease complications such as leukemic transformation and thrombosis, and  modern therapeutic strategies, including conventional drugs, allogeneic stem cell  transplantation, and experimental drugs still under study. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.


Contents:

Biology:
Update
Do we need biology studies for patient management?

Gerneral Issues in the Management of MPNs:
Critical Issues about the Diagnosis of MPNs
Patient's Information and Examinations Needed before Planning Therapy

Specific Issues of Treatment in PV and ET:
Risk classification
Goal of Therapy
First-line Therapy and Monitoring the Response in the Individual Patient
Primary and Secondary Antithrombotic Prophylaxis
When to change Therapy: Second Line Options
The Evolution in Myelofibrosis and Leukemia

Treatment of PMF:
Current Clinical Needs
Risk Stratification
Goal of Therapy: Palliation and Curative

Research Issues and Perspectives:
New drugs
Ongoing Clinical Trials
How to Design Clinical Studies in Rare Diseases


PRODUCT DETAILS

ISBN-13: 9783642249891
Publisher: Springer (Springer Berlin Heidelberg)
Publication date: February, 2012
Pages: 248

Subcategories: Haematology, Oncology

MEET THE AUTHOR

The discovery of the JAK2 V617F mutation in the majority of patients with bcr/abl-negative myeloproliferative neoplasms has stimulated a number of questions regarding the diagnosis, prognosis, and treatment of polycythemia vera, essential thrombocythemia, and primary myelofibrosis. This book provides evidence-based reviews and expert consensus results concerning the key clinical issues for patient management. Practical recommendations are provided for the optimization and standardization of management of all three types of myeloproliferative neoplasm. Risk stratification, treatment goals, and first- and second-line therapies are discussed in detail, and other relevant diagnostic and research issues are also addressed. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.